• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Elite Pharma Inc (OP: ELTP )

    0.3135 +0.0132 (+4.40%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,071,196
    Open 0.3090
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.3003
    Today's Range 0.3010 - 0.3297
    52wk Range 0.0561 - 0.3297
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
    Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
    Via Newsfile
    ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q1 2025
    Elite Pharmaceuticals just reported results for the first quarter of 2025. 
    Via InvestorPlace

    Performance

    YTD
    +125.05%
    +125.05%
    1 Month
    +78.33%
    +78.33%
    3 Month
    +86.39%
    +86.39%
    6 Month
    +106.25%
    +106.25%
    1 Year
    +254.24%
    +254.24%

    More News

    Read More
    Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
    Via Newsfile
    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
    Via Newsfile
    ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q4 2024
    Via InvestorPlace
    Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
    Via ACCESSWIRE
    Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
    Via ACCESSWIRE
    Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
    Via ACCESSWIRE
    Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
    Via Newsfile
    Treasure Hunt: 7 Penny Stocks Wall Street Hasn’t Discovered Yet
    Via InvestorPlace
    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
    Via Newsfile
    Exposures Product Safety
    7 Strong Buy Penny Stocks to Buy Now: June 2024
    Via InvestorPlace
    Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
    Via ACCESSWIRE
    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
    Via ACCESSWIRE
    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
    Via ACCESSWIRE
    Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
    Via ACCESSWIRE
    Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
    Via ACCESSWIRE
    Small Stocks, Big Potential: 7 Penny Stocks Poised for Major Gains in 2024
    Via InvestorPlace
    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
    Via ACCESSWIRE
    7 Penny Stocks With Promising Potential Catalysts in 2024
    Via InvestorPlace
    Q4 Stock Predictions: 7 Penny Stocks Ready to Roar Into 2024
    Via InvestorPlace
    Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
    Via ACCESSWIRE
    Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
    Via ACCESSWIRE
    7 Up-and-Coming Penny Stocks to Put on Your Must-Buy List
    Via InvestorPlace
    Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.